Pina Brianti

Letter: Effectiveness and Safety of Tralokinumab for the Elderly with Atopic Dermatitis in a Real-World Setting—IL AD

Giuseppe Lauletta, Luca Potestio, Cataldo Patruno, Silvia Mariel Ferrucci et autres

it (code pays fourni par la source)

Super Responder Profile Under Bimekizumab Treatment in Moderate-to-Severe Psoriasis: A Short Term Real-Life Observation—IL PSO (Italian Landscape Psoriasis)

Maria Esposito, Paolo Gisondi, Chiara Assorgi, Francesco Bellinato et autres

Bimekizumab is a humanized monoclonal antibody, targeting both IL-17A and IL-17F, that has been recently approved for the treatment of moderate-to-severe plaque psoriasis following encouraging results from four phase-III clinical trials [ 1 , 2 , 3 , 4 ]. Real-word experiences …

it (code pays fourni par la source)

Gender Influence on Bimekizumab Response in Patients with Psoriasis: Results of a Real-World Multicenter Retrospective Study—IL PSO (Italian Landscape PSOriasis)

Helena Gioacchini, Maria Esposito, Emanuele Vagnozzi, Maria Concetta Fargnoli et autres

INTRODUCTION: Several studies have demonstrated that psoriasis severity is generally greater in male patients, but it is unclear whether this gender difference may affect short-term therapeutic response. Notably, no studies have specifically investigated bimekizumab, a humanized, full-length IgG1 monoclonal antibody that acts …

it (code pays fourni par la source)

Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg—IL PSO (Italian Landscape Psoriasis)

Mario Valenti, Luciano Ibba, S. Di Giulio, Luigi Gargiulo et autres

INTRODUCTION: Tildrakizumab is a monoclonal antibody targeting interleukin (IL)-23 approved for the treatment of moderate-to-severe plaque psoriasis across two different dosages (100 mg and 200 mg). The higher dosage is recommended for patients with a body weight ≥ 90 kg or a …

it, at (code pays fourni par la source)

Five‐year drug survival of dupilumab in atopic dermatitis: Italian landscape AD real‐world study

Luigi Gargiulo, Silvia Mariel Ferrucci, Luciano Ibba, Ruggero Cascio Ingurgio et autres

Additional data supporting the findings of this manuscript are available on reasonable request to the corresponding author.

it (code pays fourni par la source)

The risk of candidiasis during treatment with bimekizumab for the management of plaque psoriasis: a 16-week multicentre real-world experience – IL PSO (Italian Landscape Psoriasis)

Matteo Megna, Diego Orsini, Chiara Assorgi, Anna Balato et autres

Anti-interleukin 17 use has been associated with a higher risk of candidiasis, as this cytokine is involved in maintaining mucosal barriers and orchestrating immune responses to fungal pathogens. We performed a real-life retrospective multicentre study aiming to assess the risk of candidiasis …

it (code pays fourni par la source)

Arrhythmias and other cardiovascular diseases in young patients (<40 years) with moderate/severe atopic dermatitis: A multicentric study in northern Italy

Giovanni Paolino, Andrea Carugno, Antonio Frontera, Franco Rongioletti et autres

The data that support the findings of this study are available from the corresponding author upon reasonable request.

it (code pays fourni par la source)

Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study – IL PSO (Italian landscape psoriasis)

Luigi Gargiulo, Luciano Ibba, Ruggero Cascio Ingurgio, Piergiorgio Malagoli et autres

PURPOSE: Tildrakizumab is a selective inhibitor of IL-23 approved for the treatment of moderate-to-severe plaque psoriasis in two dosages. We conducted a 16-week multicenter retrospective study to compare the effectiveness and safety of tildrakizumab 200 mg versus tildrakizumab 100 mg in patients …

it (code pays fourni par la source)

Bimekizumab for the Treatment of Plaque Psoriasis With Involvement of Genitalia: A 16-Week Multicenter Real-World Experience—IL PSO (Italian Landscape Psoriasis)

Diego Orsini, Piergiorgio Malagoli, Anna Balato, Luca Bianchi et autres

INTRODUCTION: Genital involvement is observed in approximately 60% of patients with psoriasis, presenting clinicians with formidable challenges in treatment. While new biologic drugs have emerged as safe and effective options for managing psoriasis, their efficacy in challenging-to-treat areas remains inadequately explored. Intriguingly, …

it, jp (code pays fourni par la source)

Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis)

Luigi Gargiulo, Alessandra Narcisi, Luciano Ibba, Anna Balato et autres

Introduction: Bimekizumab is a monoclonal antibody that targets Interleukin-17 A and F, approved for the treatment of moderate-to-severe plaque psoriasis. While bimekizumab has been evaluated in several phase-III clinical trials, real-world evidence is still very limited. Method: This multicenter retrospective study included …

it (code pays fourni par la source)

Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis: Post-Hoc Analysis of the SUPREME Study

Marina Talamonti, Filomena Russo, Giovanna Malara, Katharina Hansel et autres

Purpose: Secukinumab is a fully human monoclonal antibody that inhibits interleukin (IL)-17A approved for the treatment of moderate to severe plaque psoriasis in adults and children. We compared the efficacy and safety of secukinumab in patients aged < 65 years (adult patients) …

it (code pays fourni par la source)

New onset atopic dermatitis and psoriasis in the same patients under biologic treatments: The role of systemic treatments as a possible trigger

Giovanni Paolino, Matteo Riccardo Di Nicola, Pina Brianti, Vittoria Giulia Bianchi et autres

Atopic dermatitis (AD) and psoriasis (PsO) are among the most common diseases in the daily clinical practice. Usually, AD and PsO are reported as two diseases that cannot coexist in the same patient because this requires the activation of opposing inflammatory pathways. …

it (code pays fourni par la source)